JSW Motors has taken a bold step towards announcing its entry into India’s passenger vehicle space, placing a full front-page advertisement ...

Plug-in hybrids are starting to find favour – and for good reason, given their inherent practicality, with more than a hint ...

Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating: ...

Children with multiple nut allergies experienced significant increases in the amounts of allergens they could tolerate with ...

The FDA has approved a new four-dose, single-patient-use KwikPen for Zepbound (tirzepatide), giving patients a full month of treatment in one device.

Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) - 20 mg cohort demonstrated rapid and robust fetal hemoglobin (HbF ...

Eli Lilly has rolled out a multi-dose KwikPen version of tirzepatide, marketed as Zepbound, for chronic weight management—signaling a packaging update for one of the obesity market’s fastest-expanding ...

Eli Lilly said on Monday it received the U.S. Food and Drug Administration's approval to launch a four-dose KwikPen for its weight-loss drug Zepbound, delivering a full month of the treatment in a ...

Fleet News first reported that Renault was intending to acquire a 100% stake in the business at the start of this month. The three have now signed a binding agreement today (Monday, February 23), ...

CagriSema achieved 23% weight loss after 84 weeks of treatmentCagriSema 2.4/2.4 mg did not meet the primary endpoint of ...

Novo Nordisk stock sinks to a 52-week low after CagriSema missed its main goal in a late-stage obesity trial against Lilly's drug.